Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2250796 | 0.92 | GABRA1 (0.43) | GABRA1GABRB2SLC13A5SMN1; SMN2 | |
| SCHEMBL2252903 | 0.90 | MAOB (0.46) | HPGDSMN1; SMN2ALOX5 | |
| SCHEMBL27708319 | 0.90 | GABRA1 (0.45) | GABRA1GABRB2HPGDTAS1R3TAS1R1 | |
| SCHEMBL2246681 | 0.88 | TSHR (0.36) | GABRA1GABRB2HPGDLMNATSHR | |
| SCHEMBL2247535 | 0.84 | MMP12 (0.40) | HPGDALDH1A1 | |
| SCHEMBL2248530 | 0.83 | PDE4A (0.45) | HPGDSMN1; SMN2 | |
| SCHEMBL2249342 | 0.83 | MMP12 (0.43) | HPGDALDH1A1 | |
| SCHEMBL2251275 | 0.82 | MMP12 (0.40) | HPGDLMNATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL2249988 | 0.81 | TRPM8 (0.42) | TAS1R3TAS1R1 | |
| SCHEMBL2247854 | 0.81 | MMP2 (0.39) | GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | claimed |
| US-7998965-B2 | Glutamate aggrecanase inhibitors | WYETH LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | GABRA1 1123/4885GABRB2 454/4885HPGD 1335/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | GABRA1 1123/4885GABRB2 454/4885HPGD 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.